Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial

The latest update is out from Gyre Therapeutics ( (GYRE) ).

On May 22, 2025, Gyre Therapeutics announced that its lead compound, Hydronidone, achieved the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China. The 52-week trial demonstrated a statistically significant regression in liver fibrosis with Hydronidone compared to placebo, showing favorable safety and tolerability. This milestone positions Hydronidone as a potential first-in-class therapy for CHB-associated liver fibrosis, with plans for regulatory submission in China and further trials in the U.S.

The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Spark’s Take on GYRE Stock

According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.

The overall stock score for Gyre Therapeutics is 52. The financial performance shows improvement in operational efficiencies but is hampered by revenue volatility and liquidity challenges. Technical analysis indicates mixed momentum signals, and the high P/E ratio suggests possible overvaluation. However, the positive corporate event detailing the company’s fibrosis treatment strategy provides a boost to the stock’s outlook.

To see Spark’s full report on GYRE stock, click here.

More about Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company based in San Diego, CA, focused on developing and commercializing treatments for liver fibrosis, including MASH in the U.S. The company leverages its expertise in mechanistic studies and clinical trials for CHB-induced liver fibrosis, with a broad pipeline in China through its interest in Gyre Pharmaceuticals.

Average Trading Volume: 159,715

Technical Sentiment Signal: Hold

Current Market Cap: $1B

For an in-depth examination of GYRE stock, go to TipRanks’ Stock Analysis page.